Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SkyePharma PLC

http://www.skyepharma.com

Latest From SkyePharma PLC

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Business Strategies Financing

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals

Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy

Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on "best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper."

M & A Financing

Stock Watch: Brace For European Biotech Departures From NASDAQ

A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.

Stock Watch Financing
See All

Company Information

UsernamePublicRestriction

Register